FDA rejects Amphastar's nasal version of opioid overdose treatment

[February 21, 2017]  (Reuters) - Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the drug naloxone, which is designed to stop or reverse the effects of an opioid overdose.

The FDA's complete response letter identifies issues including user human factors study and device evaluation, the company said.

Amphastar already sells naloxone in pre-filled syringes.

(Reporting by Natalie Grover in Bengaluru)
 

[© 2017 Thomson Reuters. All rights reserved.]

Copyright 2017 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.